Lento Bio
Preclinical pharmaceutical company focused on developing small-molecule therapeutics to target molecular damage driving age-related disease
Lento Bio was formed in 2022 in collaboration with Ichor Life Sciences and Clarkson University’s Shipley Center for Innovation, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.
Our primary focus is the removal of Advanced Glycation End Products (AGEs), initially focusing on damage to the lens in presbyopia while also exploring further opportunities in systemic disease.
Visit website: https://lentobio.com/
Details last updated 29-Jun-2022
Lento Bio is also referenced in the following:
People at Lento Bio
Lento Bio News
FSU researcher and Lento Bio collaborate to treat age-related vision loss
Florida State University - 17-May-2023
Aims to cure presbyopia by restoring elasticity of the lens & inhibiting ageing process
Read more...Lento Bio raised $680,000 aiming to restore near vision in presbyopia patients
Lento Bio - 06-Sep-2022
Ichor Life Sciences leads the investment to advance anti-glycation therapies
Read more...Lento bio to launch anti-glycation drugs targeting anti-aging and presbyopia
Ichor Therapeutics - 06-Jun-2022
Lento Bio research into molecular aging damage by accelerating clinical assets
Read more...